KIIL HARRY SKIP sold $139K of MDT

KIIL HARRY SKIP (EVP & President Cardiovascular) sold 1,483 shares of Medtronic plc (MDT) at $93.65 ($0.14M total) on 2026-09-16.

Original reporting
SEC EDGAR · KIIL HARRY SKIP
Published Sep 17, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDT
Neutral
high confidence
Mentioned
$MDT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDTNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market relevance.

02

Market read

Low relevance; small insider sell unlikely to affect stock price.

03

What to watch

Holding after sale remains 42,186 shares, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑16

Background

Form 4 filings disclose insider transactions; traders monitor for material buys/sells.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

EVP Harry Skip sold 1,483 Medtronic shares for $138,883 on 2026-09-16.

Expected impact

minimal impact, likely negligible price change

Evidence & confidence

Sale size is small relative to market cap; insider is not a major holder.

Market effects

None; Medtronic operates in medical devices with no sector‑wide impact from this sale.

None; US‑listed health‑care sector unchanged.

None

Counterpoint

Insider sale could signal personal liquidity need, but size is too small to infer company outlook.

Key entities

  • Harry Skip

    EVP & President Cardiovascular at Medtronic

  • Medtronic plc

    Medical device manufacturer (ticker MDT)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 8/10

Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.